IL1R2
Interleukin-1 receptor type 2
Also known as: CD121b, IL1R2_HUMAN, IL1RB
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P27930
- Gene
- IL1R2
- Ensembl
- ENSG00000115590
- Chromosome
- 2
- Canonical length
- 398 aa
- Protein class
- Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
The protein encoded by this gene is a cytokine receptor that belongs to the interleukin 1 receptor family. This protein binds interleukin alpha (IL1A), interleukin beta (IL1B), and interleukin 1 receptor, type I(IL1R1/IL1RA), and acts as a decoy receptor that inhibits the activity of its ligands. Interleukin 4 (IL4) is reported to antagonize the activity of interleukin 1 by inducing the expression and release of this cytokine. This gene and three other genes form a cytokine receptor gene cluster on chromosome 2q12. Alternative splicing results in multiple transcript variants and protein isoforms. Alternative splicing produces both membrane-bound and soluble proteins. A soluble protein is also produced by proteolytic cleavage. [provided by RefSeq, May 2012]
Canonical amino-acid sequenceUniProt
398 residues, UniProt reviewed canonical sequence.
>P27930|IL1R2
1 MLRLYVLVMG VSAFTLQPAA HTGAARSCRF RGRHYKREFR LEGEPVALRC PQVPYWLWAS
61 VSPRINLTWH KNDSARTVPG EEETRMWAQD GALWLLPALQ EDSGTYVCTT RNASYCDKMS
121 IELRVFENTD AFLPFISYPQ ILTLSTSGVL VCPDLSEFTR DKTDVKIQWY KDSLLLDKDN
181 EKFLSVRGTT HLLVHDVALE DAGYYRCVLT FAHEGQQYNI TRSIELRIKK KKEETIPVII
241 SPLKTISASL GSRLTIPCKV FLGTGTPLTT MLWWTANDTH IESAYPGGRV TEGPRQEYSE
301 NNENYIEVPL IFDPVTREDL HMDFKCVVHN TLSFQTLRTT VKEASSTFSW GIVLAPLSLA
361 FLVLGGIWMH RRCKHRTGKA DGLTVLWPHH QDFQSYPKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IL1R2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.37
- Highest tissue expression
- 92 nTPM
Expression across tissuesHPA
Tissue
- spleen: 92 nTPM
- bone marrow: 50 nTPM
- esophagus: 41 nTPM
- rectum: 41 nTPM
- tonsil: 36 nTPM
- appendix: 34 nTPM
Single-cell type
- neutrophils: 17,941 nCPM
- neutrophil progenitors: 4,229 nCPM
- monocytes: 1,189 nCPM
- cdc: 1,097 nCPM
- monocyte progenitors: 737 nCPM
- macrophages: 288 nCPM
Immune cell
- neutrophil: 379 nTPM
- myeloid DC: 15 nTPM
- T-reg: 5.9 nTPM
- classical monocyte: 4.3 nTPM
- intermediate monocyte: 2.3 nTPM
- total PBMC: 1.5 nTPM
Brain region
- cerebral cortex: 15 nTPM
- pons: 4 nTPM
- choroid plexus: 3.5 nTPM
- thalamus: 1.5 nTPM
- basal ganglia: 1.4 nTPM
- hypothalamus: 1.1 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.69
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.11
- DepMap mean gene effect
- -0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell surface receptor signaling pathway
- immune response
- negative regulation of cytokine production involved in inflammatory response
- negative regulation of interleukin-1 alpha production
- negative regulation of interleukin-1-mediated signaling pathway
- negative regulation of protein processing
- protein processing
Molecular functions
- interleukin-1 binding
- interleukin-1 receptor activity
- interleukin-1, type II, blocking receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IL1R2 as an antibody target. Whether an autoantibody or antibody against IL1R2 could matter depends on whether native IL1R2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IL1R2 is annotated at the cell surface, where native IL1R2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label IL1R2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...